The PI3K inhibitor, taselisib (GDC-0032), has enhanced potency in PIK3CA mutant models through a unique mechanism of action

被引：4
|
作者：
Edgar, Kyle A.
Song, Kyung
Schmidt, Stephen
Kirkpatrick, Don
Phu, Lilian
Nannini, Michelle
Hong, Rebecca
Cheng, Eric
Young, Amy
Sampath, Deepak
Friedman, Lori S.
机构：
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.AM2016-370
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
370
引用
收藏
页数：3
相关论文
共 50 条
  • [1] The PI3K inhibitor, taselisib, has enhanced potency in PIK3CA mutant models through a unique mechanism of action
    Friedman, L. S.
    Edgar, K. A.
    Song, K.
    Schmidt, S.
    Kirkpatrick, D. S.
    Phu, L.
    Nannini, M. A.
    Hong, R.
    Cheng, E.
    Crocker, L.
    Young, A.
    Sampath, D.
    [J]. CANCER RESEARCH, 2017, 77
  • [2] The PI3K inhibitor, taselisib, has a unique mechanism of action that leads to enhanced potency in PIK3CA mutant models
    Song, Kyung W.
    Edgar, Kyle A.
    Kirkpatrick, Donald S.
    Phu, Lilian
    Schmidt, Stephen
    Nannini, Michelle
    Hong, Rebecca
    Cheng, Eric
    Crocker, Lisa
    Young, Amy
    Sampath, Deepak
    Friedman, Lori
    [J]. CANCER RESEARCH, 2017, 77
  • [3] Characterization of the enhanced potency of PI3K inhibitor taselisib (GDC-0032) in PI3K mutant cell lines and models
    Edgar, Kyle A.
    Nannini, Michelle
    Hong, Rebecca
    Eigenbrot, Charlie
    Schmidt, Stephen
    Young, Amy
    Sampath, Deepak
    Wallin, Jeffrey J.
    Friedman, Lori S.
    [J]. CANCER RESEARCH, 2015, 75
  • [4] Discovery of GDC-0032: A beta-sparing PI3K inhibitor active against PIK3CA mutant tumors.
    Olivero, Alan G.
    Heffron, Timothy P.
    Baumgardner, Matthew
    Belvin, Marcia
    Ross, Leanne Berry
    Blaquiere, Nicole
    Bradley, Erin
    Castanedo, Georgette
    Derynck, Mika
    Do, Steven
    Dotson, Jennafer
    Dudley, Danette
    Edgar, Kyle
    Folkes, Adrian
    Francis, Ross
    Gianetti, Tony
    Goldsmith, Richard
    Goldsmith, Paul
    Guan, Jane
    Harrison, Trevor
    Heald, Robert
    Hsu, Jerry
    Jackson, Phillip
    Jones, Graham
    Kim, Amy
    Kolesnikov, Aleks
    Lackner, Mark
    Lee, Leslie
    Lesnick, John
    Lewis, Cristina
    Mamounas, Michael
    McLean, Neville
    Murray, Jeremy
    Ndubaku, Chudi
    Nonomiya, Jim
    Pang, Jodie
    Pegg, Neil
    Prior, Wei Wei
    Salphati, Laurent
    Sampath, Deepack
    Sideris, Stephen
    Siu, Michael
    Staben, Steven
    Sutherlin, Daniel
    Ultsch, Mark
    Wallin, Jeff
    Wang, Lan
    Wiesmann, Christian
    Zhang, Xiaolin
    Friedman, Lori S.
    [J]. CANCER RESEARCH, 2013, 73 (08)
  • [5] Phase I evaluation of the PI3 kinase (PI3K) inhibitor taselisib (GDC-0032) in multiple locally advanced or metastatic PIK3CA mutant solid tumor types.
    Jhaveri, Komal L.
    Bedard, Philippe L.
    Cejalvo, Juan Miguel
    Hart, Lowell L.
    Juric, Dejan
    Kelly, Karen
    Lockhart, A. Craig
    Melnyk, Anton
    Moore, Kathleen N.
    Nemunaitis, John J.
    Oliveira, Mafalda
    Patel, Manish R.
    Sachdev, Jasgit
    Smith, David
    VanderWalde, Ari
    Ware, Joseph A.
    Jin, Huan
    Wilson, Timothy R.
    Wei, Michael C.
    Baselga, Jose
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [6] Taselisib (GDC-0032), a Potent β-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations
    Zumsteg, Zachary S.
    Morse, Natasha
    Krigsfeld, Gabriel
    Gupta, Gaorav
    Higginson, Daniel S.
    Lee, Nancy Y.
    Morris, Luc
    Ganly, Ian
    Shiao, Stephan L.
    Powell, Simon N.
    Chung, Christine H.
    Scaltriti, Maurizio
    Baselga, Jose
    [J]. CLINICAL CANCER RESEARCH, 2016, 22 (08) : 2009 - 2019
  • [7] ABSORPTION, METABOLISM, AND EXCRETION OF TASELISIB (GDC-0032), A PI3K INHIBITOR, IN RATS, DOGS, AND HUMANS
    Ma, Shuguang
    Salphati, Laurent
    Srikumar, Srikumar
    Takahashi, Ryan
    Ding, Xiao
    Pang, Jodie
    Wang, Bing
    Remarchuk, Travis
    Hsu, Jerry
    Hop, Cornelis
    Ware, Joseph A.
    Khojasteh, S. Cyrus
    [J]. DRUG METABOLISM AND PHARMACOKINETICS, 2017, 32 (01) : S74 - S75
  • [8] Part II: Development of a manufacturing route to PI3K β-sparing inhibitor GDC-0032 (Taselisib)
    Remarchuk, Travis
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2014, 248
  • [9] A phase I basket study of the PI3K inhibitor taselisib (GDC-0032) in PIK3CA-mutated locally advanced or metastatic solid tumors
    Jhaveri, Komal
    Juric, Dejan
    Saura, Cristina
    Cervantes, Andres
    Melnyk, Anton
    Patel, Manish R.
    Oliveira, Mafalda
    Gambardella, Valentina
    Ribrag, Vincent
    Ma, Cynthia X.
    Aljumaily, Raid
    Bedard, Philippe L.
    Sachdev, Jasgit C.
    Bond, John
    Jones, Surai
    Wilson, Timothy R.
    Wei, Michael C.
    Baselga, Jose
    [J]. CANCER RESEARCH, 2018, 78 (13)
  • [10] Neuregulin-1 expression correlates with sensitivity to the PI3K inhibitor, GDC-0032, outside of PIK3CA mutations in head and neck cancer
    Savage, Heidi M.
    O'Brien, Carol
    Yauch, Bob
    Settleman, Jeff
    Lackner, Mark R.
    Wilson, Timothy R.
    [J]. CANCER RESEARCH, 2014, 74 (19)
12345